{"nctId":"NCT00002651","briefTitle":"SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer","startDateStruct":{"date":"1995-05"},"conditions":["Prostate Cancer"],"count":3040,"armGroups":[{"label":"Consolidation arm I","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: bicalutamide","Drug: goserelin acetate"]},{"label":"Consolidation arm II","type":"EXPERIMENTAL","interventionNames":["Drug: bicalutamide","Drug: goserelin acetate","Other: clinical observation"]}],"interventions":[{"name":"bicalutamide","otherNames":[]},{"name":"goserelin acetate","otherNames":[]},{"name":"clinical observation","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed adenocarcinoma of the prostate\n\n  * Metastatic stage IV (stage D2)\n\n    * Any number of bone metastases by bone scan allowed\n    * Unequivocal visceral organ metastases (liver, brain, or lung) allowed\n  * No suspected second primary tumors unless metastases are histologically confirmed, including special stains (e.g., prostate specific antigen \\[PSA\\] and prostatic alkaline phosphatase \\[PAP\\])\n* For entry into late induction therapy:\n\n  * No more than 1 month from the beginning of antiandrogen therapy to the beginning of luteinizing hormone-releasing hormone (LHRH) agonist therapy\n  * No more than 6 months since initiation of current combined androgen-deprivation therapy (LHRH agonist and antiandrogen)\n  * The effectiveness of the current depot LHRH agonist would not extend beyond 8 months after initiation of combined androgen therapy\n* PSA at least 5 ng/mL\n* No acute spinal cord compression\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* Adult\n\nPerformance status:\n\n* SWOG 0-2\n\nHematopoietic:\n\n* Not specified\n\nHepatic:\n\n* Not specified\n\nRenal:\n\n* Not specified\n\nOther:\n\n* Recovered from any major infection\n* No active medical illness that would preclude study or limit survival\n* No other malignancy within the past 5 years except:\n\n  * Adequately treated basal cell or squamous cell skin cancer\n  * Adequately treated carcinoma in situ of the bladder\n  * Adequately treated other superficial cancer\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* No concurrent biological response modifier therapy\n\nChemotherapy:\n\n* No concurrent chemotherapy\n\nEndocrine therapy:\n\n* See Disease Characteristics\n* More than 1 year since any prior neoadjuvant or adjuvant hormonal therapy for a duration of no more than 4 months\n\n  * Single or combination therapy allowed\n* More than 1 year since prior finasteride for prostate cancer for a duration of no more than 9 months (less than 6 months for benign prostatic hypertrophy)\n* Prior or concurrent megestrol for hot flashes allowed\n* No other concurrent hormonal therapy\n\nRadiotherapy:\n\n* No concurrent radiotherapy other than palliation of painful bone metastases\n\nSurgery:\n\n* No prior bilateral orchiectomy\n* Recovered from any prior major surgery","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Non-inferiority test to determine if intermittent combined androgen deprivation (CAD) overall survival is not substantially worse than continuous CAD overall survival. Specifically, the trial is designed for a one-sided test of the hypothesis that the hazard ratio of intermittent CAD to continuous CAD is 1.2. The assumptions used to compute the trial size are an overall type I error rate of 0.05 and a type II error of 0.10 (power = 0.9).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Physical Functioning as Measured by the SF-36","description":"This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. Change from Baseline in SF-36 Score at 3 Months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.74","spread":"0.7366"},{"groupId":"OG001","value":"0.09","spread":"0.8084"}]}]}]},{"type":"PRIMARY","title":"Emotional Functioning as Measured by the SF-36 Mental Health Inventory","description":"This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. Change from Baseline in SF-36 Score at 3 Months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":"0.6804"},{"groupId":"OG001","value":"1.92","spread":"0.7241"}]}]}]},{"type":"PRIMARY","title":"Erectile Dysfunction","description":"This outcome was assessed by having patients report whether they had erectile dysfunction (a score of 1) or no erectile dysfunction (a score of 0). This analysis looks at change from Baseline to 3 Months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"-7","spread":null}]}]}]},{"type":"PRIMARY","title":"High Libido","description":"This outcome was assessed by having patients report whether their interest in sexual activities was very high, high, or moderate (a score of 1) or low or very low (a score of 0). This outcome measure is reporting a change from baseline in the percentage of participants with High Libido at 3 months. \"High Libido\" is defined as very high, high or moderate interest in sexual activities.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"PRIMARY","title":"Vitality","description":"This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. This analysis looks at mean change from Baseline score to 3 Months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.42","spread":"0.7379"},{"groupId":"OG001","value":"-0.11","spread":"0.8154"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Global Perception of Quality of Life","description":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Social Functioning","description":"Mean of the change in social functioning from randomization","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Role Functioning","description":"Mean of the change in role functioning from randomization","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"General Symptoms","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":732},"commonTop":["Hot flashes","Fatigue/malaise/lethargy","Erectile impotence","Bone pain","Libido loss"]}}}